---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-22-000038"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:26:21.451925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q3 revenue $217M (+57% YoY); raises DMD full-year guidance; secures $350M Blackstone financing

## Summary
- Q3 total revenue $217.1M (+57% YoY); net product revenue $134.2M, royalty and collaboration $82.9M.
- DMD franchise net product rev $131.4M (Translarna $76.6M, Emflaza $54.8M); full-year DMD guidance raised to $490-500M.
- Strategic financing from Blackstone: initial $350M at close, option for additional $650M low-cost, low-dilution capital.
- Net loss improved to $109.3M from $133.6M in Q3 2021; cash $288.4M as of Sep 30, 2022.
- Clinical: EMA submission for Translarna standard approval; FDA meeting for Translarna US NDA; Upstaza BLA expected H1 2023.

## SEC filing metadata
- accession: 0001070081-22-000038
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/0001070081-22-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/tmb-20221027x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-22-000038
- JSON: https://secwatch.observer/filing/0001070081-22-000038.json
- Plain text: https://secwatch.observer/filing/0001070081-22-000038.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: revenue $217.1 million, net income $(109.3) million. Guidance raised.
  - Period: the quarter ended September 30, 2022
  - Revenue: $217.1 million
  - Net income: $(109.3) million
  - Guidance: raised
  - Result: reported results
  source text: into this Item 2.02. ​ --- EX-99.1 (EX-99.1) --- PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth – - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008122000038/0001070081-22-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.